In both cases, the tumor cell expression of programmed death ligand-1 was negative, and CD4<sup>+</sup> and CD8<sup>+</sup> cells were observed in the tumor.<h4>Conclusion</h4>Combined immunotherapy with pembrolizumab and axitinib may be effective for metastatic renal collecting duct carcinoma. Here, CD4 is linked to neoplasm.